View metadata, citation and similar papers at core.ac.uk brought to you by CORE

provided by Elsevier - Publisher Connector

Kidney International, Vol. 66 (2004), pp. 974–977

Mutations in the uromodulin decrease urinary excretion of Tamm-Horsfall

ANTHONY J. BLEYER,THOMAS C. HART,ZAK SHIHABI,VICKI ROBINS, and JOHN R. HOYER

Section on Nephrology, Wake Forest University School of Medicine Medical Center, Winston-Salem, North Carolina; Department of Human Genetics, Graduate School of Public Health University of Pittsburgh, Pittsburgh, Pennslyvania; Human and Craniofacial Genetics Section, National Institute of Dental and Craniofacial Research, and National Institutes of Health, Bethesda, Maryland; Department of Pathology, Wake Forest University School of Medicine, Medical Center, Winston-Salem, North Carolina; and Department of Pediatrics and Department of Medicine, University of Pennsylvania and Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania

Mutations in the uromodulin gene decrease urinary excretion tic disease type 2 (MCKD 2) or as uromodulin of Tamm-Horsfall protein. (UMOD)-associated kidney disease leads to precocious Background. Mutations in the uromodulin (UMOD) and progressive chronic renal failure. Genetic analy- gene that encodes Tamm-Horsfall protein (THP) cause an autosomal-dominant form of chronic renal failure. We have now sis has recently shown that mutations in the UMOD gene investigated effects of UMOD gene mutations on protein ex- that encodes Tamm-Horsfall protein (THP) result in this pression by quantitatively measuring THP excretion. autosomal-dominant condition [1–5]. Methods. THP excretion was determined by enzyme-linked THP is produced exclusively in the thick ascending immunosorbent assay (ELISA) of collections obtained limb of Henle’s loop (TAL) and early distal convoluted from 16 related individuals with a 27 bp deletion in the UMOD gene and seven individuals with other UMOD mutations. THP tubule [6]. This surface membrane protein is the most excretion of 22 control subjects (18 genetically related individ- abundant protein in normal urine [7]. Urinary THP ex- uals and four spouses in the UMOD deletion family) was also cretion has been evaluated by either 24-hour excretion determined. [7–9] or in relation to creatinine excretion [9, 10]. Urinary Results. The16individuals carrying the deletion mutation ex- THP decreases with declining glomerular filtration rate creted 5.8 ± 6.3 mg THP/g creatinine into their urine. The 18 unaffected relatives from the same family excreted 40.8 ± 9.7 mg (GFR) [9, 10]. Since the ratio of urinary THP to creatinine THP/g creatinine (P < 0.0001) and the four spouses excreted is stable after 4 years of age [10], the THP excretion of 43.9 ± 25.1 mg THP/g creatinine (P < 0.0001 vs. individuals adults and children can be compared. Although THP had with the deletion mutation). THP excretion of sevem individu- been initially described nearly 4 decades earlier [11], the als with other UMOD gene mutations was also extremely low nucleotide sequence encoding THP was determined dur- (range of 0.14 to 5.9 mg THP/g creatinine). All individuals with UMOD mutations had low THP excretion, irrespective of gen- ing investigations of a subspecies of this protein isolated der, glomerular filtration rate (GFR), or age. from the urine of pregnant women. Since this protein had Conclusion. These studies quantitatively show that the been called uromodulin [12], the nucleotide sequence was autosomal-dominant gene mutations responsible for UMOD- designated as the UMOD gene. associated kidney disease cause a profound reduction of THP In the present studies, we have investigated the effect excretion. We speculate that this suppression of normal THP excretion reflects deleterious effects of mutated THP within of mutations in the UMOD gene on protein expression the kidney. Such effects may also play an important role in the by quantitatively determining THP excretion. A sensi- pathogenesis of the progressive renal failure observed in pa- tive enzyme-linked immunosorbent assay (ELISA) was tients with UMOD gene mutations. used to measure the excretion of THP by members of an extended family that share a deletion in the UMOD The clinical condition known as either familial juvenile gene, unaffected individuals in this family, and a smaller hyperuricemic nephropathy (FJHN) or medullary cys- number of patients with other mutations of the UMOD gene. Keywords: Tamm-Horsfall protein, familial juvenile hyperuricemic nephropathy, medullary cystic kidney disease, uromodulin-associated kidney disease, human. METHODS All participants provided informed consent to a study Received for publication January 9, 2004 and in revised form March 17, 2004, and April 13, 2004 protocol approved by the Institutional Review Board Accepted for publication April 21, 2004 of Wake Forest University School of Medicine. Urine and blood samples were obtained from individuals from C 2004 by the International Society of Nephrology five families with known disease-associated mutations in 974 Bleyer et al: Mutations decrease Tamm-Horsfall protein excretion 975

Table 1. Features of families with mutations in the gene that encodes Tamm-Horsfall protein (THP) Age Serum Urinary THP/ Urinary THP Family Mutation years creatinine creatinine ratio mg/24 hours 1(N = 16) g.1966 1922deletion 37.9 ± 14.2 1.85 ± 0.93 6.0 ± 6.1 5.5 ± 5.3 2g.1990C>G 16.4 1.3 2.5 6.5 35.5 2.2 0.56 0.53 3g.1880G>A 10.9 0.8 5.9 3.0 23.6 2.0 4.4 4.5 35.7 2.2 0.14 0.11 4g.2086T>C 17.0 1.1 5.6 3.2 5g.2105G>A 51.0 2.0 1.3 1.3 1 (unaffected) 29.2 ± 17.2 0.95 ± 0.13 40.8 ± 9.7a 43.8 ± 27.9a (N = 18) (N = 17) (N = 18) (N = 18)b 1 (spouses) (N = 4) 47.5 ± 8.3 1.05 ± 0.17 43.9 ± 25.1a 55.4 ± 36.8a

aP < 0.0001 vs. family 1 with deletion mutation. bRange of 21 to 119 mg THP/24 hours. the UMOD gene. They collected 24-hour urinary sam- clonal rabbit anti-THP prepared as previously described ples while on an ad libitum diet. Each urine sample [17], and the secondary antibody was an affinity purified was preserved with 1 mg/mL thimerosal (Sigma-Aldrich, peroxidase-conjugated goat antirabbit IgG (Jackson Im- St. Louis, MO, USA) and 0.02% sodium azide (Fisher munoResearch, West Grove, PA, USA). Concentrations Scientific, Hampton, NH, USA). Serum samples for uric of THP in samples were calculated using the curve de- acid and creatinine were also obtained. rived from the optical densities of THP standards run on The creatinine measurements were performed by the the same plate. The THP level of the urine sample from Jaff´ealkaline picrate kinetic method [13]. The uric acid one subject was below the detection limit for the assay measurements were performed on the ADVIA 1650 (∼1 ng/mL after dilution) and was assigned a value of Chemistry System (Bayer Diagnostics, Tarrytown, NY, 0.01 lg/mL for calculations and graphing. All results of USA). This uric acid method is based on the Fossati enzy- groups are expressed as mean ± 1SD. Potential differ- matic reaction using uricase with a Trinder-like end point ences between groups were evaluated by the unpaired [14]. Student t test.

Genetic studies RESULTS Peripheral venous blood samples were obtained by Urine and blood samples were obtained from the standard venipuncture and genomic DNA was isolated 45 individuals listed in Table 1. Gene sequence analy- using the QIAmp blood kit (Qiagen, Valencia, CA, sis showed that 16 individuals from a very large fam- USA). Polymerase chain reaction (PCR) amplification of ily (family 1) had a 27 bp deletion (g.1966 1922del) in the UMOD gene was performed using oligonucleotide exon 4 of the UMOD gene. The clinical characteristics primers [1]. Amplified DNA was purified with the QI- of this family have been extensively described [18]. The Aquick PCR Purification Kit (Qiagen) and was se- affected individuals from four additional families had sin- quenced using the BigDye Terminator Cycle Sequencing gle nucleotide mutations in exon 4 of the UMOD gene Kit on an ABI 3700 DNA Analyzer (Applied Biosystems, as follows: three individuals had a g.1990C>G mutation Foster City, CA, USA) by the Genomics and Proteomics (family 2), two individuals had a g.1880G>A mutation Core Laboratories of the University of Pittsburgh. Se- (family 3), one individual had a g.2086T>C mutation [1] quence analysis was performed with Sequencher 4.1 soft- (family 4), and one individual had a g.2105G>A muta- ware (GeneCodes, Ann Arbor, MI, USA). tion (family 5). Sequence analysis of the 18 additional genetically related individuals in family 1 in the present study revealed no mutations in exon 4 of the UMOD gene. Immunoassay Analysis of samples from four genetically unrelated fam- The ELISA for THP was performed using a general ily 1 spouses provided additional control observations. protocol previously described in detail for human uri- The urinary THP excretion of affected members of nary osteopontin [15, 16] with the following modifica- family 1 was markedly lower than that of unaffected fam- tions for THP. Urine samples were diluted with a 0.01 ily members (Table 1). The difference between groups mol/L PO4, pH 9.3, buffer prior to coating of 96-well Max- within this kindred was highly significant (P < 0.0001) isorb microtiter plates (Nunc, Rochester, NY, USA) us- for comparisons of either the ratio of milligram THP to ing a series of twofold dilutions after an initial dilution of gram urinary creatinine or milligram THP per 24 hours. urine at 1:100 or 1:400. The primary antibody was a poly- Differences in the level of THP excretion by affected 976 Bleyer et al: Mutations decrease Tamm-Horsfall protein excretion

DISCUSSION 80 F#1 mutation F#1 unaffected F#2-#5 mutation F#1 spouse All 16 members of family 1 sharing a UMOD gene 60 mutation had lower urinary excretion of THP than any family members without the mutation (Figs. 1 and 2) 40 (Table 1). The urinary excretion of THP was low, even at the earliest ages before developing chronic renal fail- 20 ure. Very low urinary THP excretion was also observed in all seven individuals with other mutations in exon 4 of the UMOD gene (Table 1) (Figs. 1 and 2) regardless of Urinary THP/creatinine ratio 0 0.0 1.0 2.0 3.0 4.0 age, gender, or level of renal function. Serum creatinine, mg/dL The present quantitative evidence for markedly de- creased THP excretion by patients with mutations in Fig. 1. Comparison of urinary Tamm-Horsfall protein exon 4 of the UMOD gene is consistent with and ex- (THP)/creatinine ratios to the serum creatinine levels of indi- viduals with a mutation in the gene encoding THP in family 1 and in tends recent reports [4, 19]. These studies described families 2 to 5 with values of the unaffected individuals in family 1 and decreased THP on Western blots of urine from a small family 1 spouses. number of patients with single nucleotide mutations of the UMOD gene [4, 19]. Decreased THP excretion ap- pears to be a general feature of chronic renal failure [9, 80 10]. However, Dahan et al [4] recently reported that THP detected on Western blots of urine from patients with cre- 60 atinine clearances less than 40 mL/min was decreased in patients with UMOD mutations when compared to THP 40 of patients with other causes of renal failure. Our studies early in the disease provide additional evidence that re- 20 nal failure is not the primary factor causing the markedly decreased THP excretion by patients with UMOD mutations. Urinary THP/creatinine ratio 0 010203040506070 A precise correlation of markedly decreased THP ex- Age, years cretion with UMOD mutations detected by genetic test- ing was demonstrated in the present study. This suggests Fig. 2. Comparison of urinary Tamm-Horsfall protein that, in the future, tests of THP excretion may provide a (THP)/creatinine ratios to the age of the individuals in the same groups as in Figure 1 using the same set of symbols. noninvasive way to clinically evaluate young children in families with known UMOD mutations. However, DNA testing is now available (Athena Diagnostics, Worcester, individuals and the spouses in family 1 were also highly MA, USA), while measurements of THP excretion are significant (P < 0.0001 for both comparisons). now performed only in a research setting. Thus, deter- Many affected members of family 1 had higher serum mining THP excretion is not currently a practical screen- creatinine levels, a finding consistent with their under- ing test for the relatively small number of individuals in lying disorder. The GFR of patients with UMOD gene families with this disease. mutations usually begins to decline in the late teens. The 616 amino acid sequence of normal THP con- THP excretion of affected individuals was lowest at high tains an abundance of domains with an extremely high serum creatinine levels (Fig. 1). However, it is notewor- cysteine content. Such cysteine residues are believed to thy that the three affected family 1 members with the be important determinants of the quaternary structure lowest serum creatinine levels (0.8 mg/dL) (the GFR es- of normal THP via intrachain disulfide bonds [20]. It is timated for these three individuals using the four variable thus noteworthy that most of the described mutations in modified MDRD equation [abstract; Levey AS et al, J the UMOD gene have occurred in the exons encoding Am Soc Nephrol 11:155A, 2000] was 98 ± 6.0 mL/min/ cysteine-rich domains. Indeed, most of these mutations 1.73 m2) had very low THP excretion in compari- have involved a cysteine substitution [1]. The formation son to that of unaffected family members. The urinary of disulfide bonds in the endoplasmic reticulum may be THP/creatinine ratio for these three individuals was critical for the subsequent export of THP from TAL cells 15.3 ± 2.3 (P = 0.0003 vs. the 18 unaffected family [21]. This concept is supported by the recent observation members). The relationship of THP excretion to age is of THP deposits in the endoplasmic reticulum in TAL shown in Figure 2. Affected individuals had low urinary cells in kidneys of individuals with UMOD gene muta- THP/creatinine ratios at all ages. tions [4, 19]. Bleyer et al: Mutations decrease Tamm-Horsfall protein excretion 977

Our studies expand the types of UMOD gene muta- 2. TURNER JJ, STACEY JM, HARDING B, et al: Uromodulin mutations tions influencing THP excretion by showing that not only cause familial juvenile hyperuricemic nephropathy. J Clin En- docrinol Metab 88:1398–1401, 2003 missense mutations, but also deletions markedly decrease 3. BLEYER AJ, TRACHTMAN H, SANDHU J, et al: Renal manifestations of THP excretion. The mutation in family 1 (g.1966 1922del) a mutation in the uromodulin (Tamm Horsfall Protein) gene. Am J causes deletion of 9 amino acids from the THP peptide Kidney Dis 42:E20–E26, 2003 4. DAHAN K, DEVUYST O, SMAERS M, et al:Acluster of mutations in the sequence. Single copy mutations that completely block uromodulin gene cause familial juvenile hyperuricemic nephropa- production of a protein (null mutation) would not be ex- thy with abnormal excretion of uromodulin. JAmSoc Nephrol pected to influence secretion of the protein encoded by 14:2883–2893, 2003 5. WOLF MT, MUCHA BE, ATTANSIO M, et al:Mutations of the uromod- the other (normal) allele. Thus, a null mutation of the ulin gene in MCKD type 2 patients cluster in exon 4, which encodes UMOD gene would be expected to reduce THP excre- 3 EGF-like domains. Kidney Int 64:1580–1587, 2003 tion to half of normal. However, our quantitative studies 6. SERAFINI-CESSI F, MALAGOLINI N, CAVALLONE D: Tamm-Horsfall : Biology and clinical relevance. Am J Kidney Dis of individuals with this deletion mutation showed that 42:658–676, 2003 levels of excretion were much less than half the amount 7. LYNN KL, MARSHALL RD: Excretion of Tamm-Horsfallglycoprotein of THP excreted by their unaffected relatives. Therefore, in renal disease. Clin Nephrol 22:253–257, 1984 8. DAWNAY AB, THORNLEY C, CATTELL WR: An improved radioim- it is likely that excretion of normal THP molecules is munoassay for urinary Tamm-Horsfall glycoprotein. Biochem J suppressed by presence of the mutated protein. Since the 206:461–465, 1982 decrease of THP excretion occurs early when the GFR is 9. THORNLEY C, DAWNAY A, CATTELL WR: Human Tamm-Horsfallgly- coprotein: Urinary and plasma levels in normal subjects and patients normal, the decreased THP excretion is not simply due with renal disease determined by a fully validated radioimmunoas- to renal failure. say. Clin Sci 68:529–535, 1985 The production of a mutated protein in this disease 10. OLLIER-HARTMANN MP, POUGET-ABADIE C, BOUILLIE J, HARTMANN L: Variations of urinary Tamm-Horsfall protein in humans during may have deleterious effects within the kidney that are the first thirty years of life. Nephron 38:163–166, 1984 analogous to effects found as a consequence of dominant 11. TAMM I, HORSFALL FL: Characterization and separation of an in- interference caused by mutations in other diseases such as hibitor of viral hemagglutination present in urine. Proc Soc Exp Biol Med 74:108–114, 1950 ataxia telangiectasia [22] and pseudoachondroplasia [23]. 12. PENNICA D, KOHR WJ, KUANG W, et al: Identification of human UMOD-associated kidney disease appears to be one of uromodulin as the Tamm-Horsfall urinary glycoprotein. Science a growing number of endoplasmic reticulum storage dis- 236:83–88, 1987 13. TIETZ NW: Clinical Guide to Laboratory Tests, 3rd ed., Philadelphia, eases, in which an abnormal protein precipitates in the en- WB Saunders Company, 1995, pp 186–187 doplasmic reticulum with deleterious consequences [24]. 14. FOSSATI P, PRENCIPE L, BERTI G: Use of 3,5-dichloro-2- We speculate that such effects play an important role in hydroxybenzenesulfonic acid/4 aminophenazone chromogenic sys- tem in direct enzymic assay of uric acid in serum and urine. Clin the pathogenesis of the progressive renal failure observed Chem 26:227–231, 1980 in patients with UMOD gene mutations. 15. SHIRAGA H, MIN W, VANDUSEN WJ, et al: Inhibition of calcium oxalate crystal growth in vitro by uropontin: Another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA ACKNOWLEDGMENTS 89:426–430, 1992 These studies were supported by research grants from the National 16. MIN W, SHIRAGA H, CHALKO C, et al: Quantitative studies of Institutes of Health DK62252 and DK33501 and by a grant from the human urinary excretion of uropontin. Kidney Int 53:189–193, National Kidney Foundation of North Carolina, Inc. The institutions of 1998 two of the authors (Dr. Anthony Bleyer and Dr. Thomas Hart) have a 17. HOYER JR, RESNICK JS, MICHAEL AF, VERNIER RL: Ontogeny licensing agreement with Athena Diagnostics, Inc., for genetic testing of of Tamm-Horsfall urinary glycoprotein. Lab Invest 30:757–761, individuals suspected of suffering from uromodulin-associated kidney 1974 disease. None of the authors have any ownership interest in Athena 18. BLEYER AJ, WOODARD AS, SHIHABI Z, et al: Clinical characteriza- Diagnostics, Inc. tion of a family with a mutation in the uromodulin (Tamm-Horsfall glycoprotein) gene. Kidney Int 64:36–42, 2003 Reprint requests to Anthony J. Bleyer, M.D., Section on Nephrol- 19. RAMPOLDI L, CARIDI G, SANTON D, et al:Allelism of MCKD, FJHN, ogy, Wake Forest University School of Medicine, Medical Center Blvd, and GCKD caused by impairment of uromodulin export dynamics. Winston-Salem, NC 27157. Hum Mol Genet 12:3369–3384, 2003 E-mail: [email protected] 20. KUMAR S, MUCHMORE A: Tamm-Horsfall protein—Uromodulin (1950–1990). Kidney Int 37:1395–1401, 1990 Correspondence to John R. Hoyer, M.D., The Children’s Hospital of 21. MALAGOLINI N, CAVALLONE D, SERAFINI-CESSI F: Intracellular trans- Philadelphia, 702 Abramson Research Building, 3615 Civic Center port, cell-surface exposure and release of recombinant Tamm- Boulevard, Philadelphia, PA 19104–4318. Horsfall glycoprotein. Kidney Int 52:1340–1350, 1997 E-mail: [email protected] 22. SCOTT SP, BENDIX R, CHEN P, et al: Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. Proc Natl Acad Sci USA 99:925–930, REFERENCES 2002 23. DINSER R, ZAUCKE F, KREPPEL F, et al: Pseudoachondroplasia is 1. HART TC, GORRY MC, HART PS, et al:Mutations of the uromodulin caused through both intra- and extracellular pathogenic pathways. gene are responsible for medullary cystic kidney disease 2 and famil- J Clin Invest 4:505–513, 2002 ial juvenile hyperuricaemic nephropathy. JMed Genet 39:882–892, 24. RUTISHAUSER J, SPIESS M: Endoplasmic reticulum storage diseases. 2002 Swiss Med Wkly 132:211–222, 2002